Leishmaniasis is a diverse group of clinical syndromes caused by protozoan parasites of the
genus Leishmania. The clinical manifestation of the disease varies from self-limiting …

Leishmaniasis is caused by protozoan Leishmania parasites that are transmitted through
female sandfly bites. The disease is predominantly endemic to the tropics and semi-tropics …

With more than 12 million people affected worldwide, 2 million new cases occurring per
year, and the rapid emergence of drug resistance and treatment failure, leishmaniasis is an …

Leishmaniasis remains a public health problem worldwide, affecting approximately 12
million people in 88 countries; 50 000 die of it each year. The disease is caused by …

Background/Purpose Leishmania (L.) tropica is the causative agent of different forms of
human leishmaniasis. There is little information about the role of Leishmania-specific …

Major surface protease (MSP or GP63) is the most abundant glycoprotein localized to the
plasma membrane of Leishmania promastigotes. MSP plays several important roles in the …

Visceral leishmaniasis is deadly if not treated, and development of a vaccine with long-term
immunity remains a challenge. In this study, we showed that cationic distearoyl …

To develop an efficient liposomal vaccine delivery system, the size of liposomes is critical to
their adjuvant activities. In the present study, liposomes with different sizes (100, 400 …

Leishmania infection continues to have a major impact on public health inducing significant
morbidity and mortality mostly in the poorest populations. Drug resistance, toxicity and side …

This study aimed to evaluate the efficacy of glucantime and amphotericin B (AmB)
encapsulated in niosome against cutaneous leishmaniasis (CL) using in vitro and in vivo …